The literature converges on a central thesis: cell-based cancer immunotherapy is undergoing a structural transition away from costly, logistically constrained autologous CAR-T manufacturing toward platforms designed for scalability, accessibility, and reduced complexity. The dominant paradigm shift is the move from ex vivo manufacturing—extraction, engineering, and expansion of a patient's own T cells—to in vivo gene delivery, where CAR-generating constructs (delivered via viral vectors or lipid nanoparticles) are administered directly to patients, generating CAR-expressing cells inside the body. This approach, reviewed by groups such as Dana-Farber/MIT and summarized in journals like Blood, is positioned as a direct solution to the twin bottlenecks of manufacturing complexity and cost that currently restrict patient access, particularly in resource-limited settings such as Latin America. Early clinical reports already demonstrate proof-of-concept safety and antitumor activity for in vivo-generated CAR T cells, even as open questions remain around optimal delivery routes, ideal disease indications, and long-term durability of response.
A parallel and complementary trend is the diversification of the cellular chassis itself beyond conventional autologous CAR-T cells. CAR-NK, CAR-M (macrophage), tumor-infiltrating lymphocyte, and iPSC-derived immune effector platforms are emerging as next-generation alternatives, each built on the same core Chimeric Antigen Receptor architecture but offering distinct safety and manufacturing profiles. CAR-NK therapy in particular is highlighted for its potential safety advantages over CAR-T and its natural compatibility with allogeneic, off-the-shelf production—an attribute reinforced by gain-of-function engineering strategies designed to enhance NK cell potency and persistence. Together with allogeneic cell therapy platforms more broadly, these approaches directly target the access and scalability limitations inherent to patient-specific autologous manufacturing, enabling distribution beyond specialized academic centers.
Mechanistically, both trend lines—in vivo generation and alternative cell platforms—converge on gene delivery technology as the pivotal enabling layer. Viral vectors remain the traditional workhorse but are increasingly complemented or replaced by non-viral systems (notably lipid nanoparticles), which reduce manufacturing complexity and vector-related safety concerns while broadening therapeutic accessibility. This shared dependency on delivery-system innovation links CAR-T, CAR-NK, and CAR-M development under a common technological throughline.
Collectively, these entities describe an ecosystem-level transformation in cancer cell therapy: a move from bespoke, expensive, single-patient manufacturing toward modular, scalable, and potentially off-the-shelf or fully in vivo therapeutic paradigms. The unifying goal across in vivo engineering, allogeneic platforms, non-viral delivery, and alternative effector cells (NK, macrophage, iPSC-derived) is the same—expanding the CAR-based immunotherapy toolbox while systematically dismantling the cost, complexity, and access barriers that have historically confined CAR-T therapy to a narrow set of specialized centers and patient populations.